Human monoclonal antibodies to hantavirus and methods of use therefore
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-12534512-B2
Publication Date
2026-01-27
Expiration Date
Abstract
The present disclosure is directed to antibodies binding to and neutralizing hantavirus and methods for use thereof.
Core Innovation
The invention relates to immunodetection of hantavirus using antibodies or antibody fragments that bind a hantavirus antigen and thereby enable detection of a hantavirus infection in a subject. Antibody definitions are provided through heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences, with alternative CDR sequence combinations enumerated by SEQ ID NOS.
The described workflow includes contacting a sample from a subject with the defined antibody or antibody fragment and detecting hantavirus in the sample by binding to the hantavirus antigen. The document also addresses determination of antigenic stability and antigen integrity for a hantavirus antigen by detectable binding of the antibody to the antigen.
This binding readout is used to determine antigenic stability, antigen amount, correct antigen conformation and/or correct antigen sequence. The disclosure also provides treating or reducing the likelihood of infection by delivering to a subject an antibody or antibody fragment comprising the specified CDR sequences, and describes vaccine formulations comprising one or more expression vectors encoding the antibody or antibody fragment, as well as engineered cells encoding the antibody or antibody fragment.
Claims Coverage
The provided independent claims include multiple inventive features. Across the claims, the core inventive element is antibody specificity defined by enumerated CDRH1-3 and CDRL1-3 SEQ ID NOS and detectable binding to a hantavirus antigen.
Hantavirus detection using CDR-defined antibody binding
A method of detecting a hantavirus infection in a subject by contacting a sample with an antibody or antibody fragment comprising CDRH1-3 and CDRL1-3 sequences defined by enumerated SEQ ID NOS, and detecting hantavirus in the sample by binding of the antibody or antibody fragment to a hantavirus antigen.
Antigen integrity assessment via CDR-defined antibody binding
A method of determining the antigenic stability, antigen amount, correct antigen conformation and/or correct antigen sequence of a hantavirus antigen by contacting a sample comprising the antigen with a first antibody or antibody fragment comprising CDRH1-3 and CDRL1-3 sequences defined by enumerated SEQ ID NOS, and determining the properties by detectable binding of the first antibody or antibody fragment to the antigen.
Sequence-defined hantavirus antibodies
A monoclonal antibody or antigen-binding fragment thereof comprising heavy chain complementarity determining region (CDRH1-3) sequences and light chain complementarity determining region (CDRL1-3) sequences comprising enumerated SEQ ID NOS.
Treating or reducing likelihood of hantavirus infection
A method of treating a subject infected with hantavirus, or reducing the likelihood of infection of a subject at risk of contracting hantavirus, comprising delivering to the subject an antibody or antibody fragment comprising CDRH1-3 and CDRL1-3 sequences defined by enumerated SEQ ID NOS.
Protecting placenta and/or fetus
A method of protecting the health of a placenta and/or fetus of a pregnant subject infected with or at risk of infection with hantavirus comprising delivering to the subject an antibody or antibody fragment comprising CDRH1-3 and CDRL1-3 sequences defined by enumerated SEQ ID NOS.
Vaccine formulation encoding sequence-defined antibodies
A vaccine formulation comprising one or more expression vectors encoding an antibody or antibody fragment comprising CDRH1-3 and CDRL1-3 sequences defined by enumerated SEQ ID NOS.
Engineered cell encoding sequence-defined antibodies
An engineered cell encoding an antibody or antibody fragment comprising CDRH1-3 and CDRL1-3 sequences defined by enumerated SEQ ID NOS.
The claim coverage centers on antibodies and antibody fragments defined by specified CDRH1-3 and CDRL1-3 sequence identities, used for detecting hantavirus infection, assessing antigenic stability, amount, conformation, and sequence, treating infection or reducing infection likelihood, protecting placenta and/or fetus, and in vaccine formulations and engineered cells.
Stated Advantages
Detecting hantavirus infection by binding of a CDR-defined antibody or antibody fragment to a hantavirus antigen.
Treating a subject infected with hantavirus or reducing the likelihood of infection in a subject at risk.
Determining antigenic stability, antigen amount, correct antigen conformation and/or correct antigen sequence of a hantavirus antigen by detectable binding.
Protecting the health of a placenta and/or fetus of a pregnant subject infected with or at risk of infection with hantavirus.
Providing vaccine formulations comprising expression vectors encoding the specified antibody or antibody fragment.
Providing engineered cells encoding the specified antibody or antibody fragment.
Documented Applications
Detecting hantavirus infection in a subject by contacting a subject sample with the specified antibody or antibody fragment and detecting binding to hantavirus antigens.
Treating a subject infected with hantavirus or reducing the likelihood of infection of a subject at risk by delivering the specified antibody or antibody fragment.
Protecting the health of a placenta and/or fetus in a pregnant subject infected with or at risk of hantavirus infection.
Determining antigenic stability, antigen amount, correct antigen conformation and/or correct antigen sequence of a hantavirus antigen using antibody binding readout.
Vaccine formulation using one or more expression vectors encoding the specified antibody or antibody fragment.
Use of an engineered cell encoding the specified antibody or antibody fragment.
Interested in licensing this patent?